Last updated on February 2008
Sorafenib Long Term Extension Program (STEP)
Brief description of study
This study will enable patients receiving sorafenib (Nexavar) in the completed Bayer/Onyx sponsored clinical trials to continue treatment. During the entire course of the study, numerous patients will be treated with sorafenib. Involvement in this study will be depending on whether the patient benefits from the treatment or not, based on the physician's judgment and the results of particular additional examinations. Overall, participation in this study will help to evaluate the safety and efficacy of treatment with sorafenib.
Clinical Study Identifier: NCT00625378